Senores Pharmaceuticals Limited, established in December 2017 and later converted to a public limited company in September 2023, is a global research-driven pharmaceutical company specializing in the development and production of pharmaceutical products. The company primarily focuses on Regulated Markets, particularly in the US and Canada, with a strategy centered on mid-market specialty and complex niche products. Senores Pharma boasts approvals for 19 ANDAs and operates across various therapeutic areas and dosage forms. Expanding its footprint, the company is active in Emerging Markets across 43 countries and has a Critical Care Injectables business serving hospitals in India. Additionally, it manufactures APIs for domestic and SAARC markets.
The company has pursued an aggressive growth strategy through acquisitions and business diversification. In 2021, it launched its wholly owned subsidiary, Senores Pharmaceuticals Inc., in the US and entered the API segment after acquiring Ratnagene Lifescience Private Limited. In 2023, Senores expanded further, acquiring a majority stake in Havix Group Inc. and Ratnatris Pharmaceuticals Private Limited, consolidating its presence in both regulated and emerging markets. It recently entered the US CMO segment by launching a product in collaboration with Jubilant Cadista Pharmaceuticals Inc. in 2024.
Senores Pharma is gearing up for an IPO with plans to issue 2.7 million equity shares through Offer for Sale and raise Rs 500 crores via Fresh Issue. This fundraising initiative is expected to fuel the company's growth trajectory and strengthen its position in regulated and emerging pharmaceutical markets.
